Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.

Gerum Gashaw GebeyehuJoseph FiskeEleanor LiuJimmy K LimdiGiacomo BroglioChristian SelingerVioleta RazsanskaitePhilip J SmithPaul K FlanaganSreedhar Subramanian

Published in: Digestive diseases and sciences (2022)

We observed comparable safety and effectiveness for ustekinumab and vedolizumab in treating elderly CD patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
randomized controlled trial
prognostic factors
middle aged
patients with inflammatory bowel disease